valsartan has been researched along with transforming growth factor beta in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 15 (71.43) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Bieringer, M; Breu, V; Dechend, R; Fiebeler, A; Haller, H; Luft, FC; Müller, DN; Park, JK; Schmidt, F; Shagdarsuren, E | 1 |
| Hannan, RD; Krum, H; Lim, S; See, F; Tzanidis, A; Ugoni, AM | 1 |
| Lau, CP; Tipoe, GL; Wing-Hon Lai, K; Yu, CM | 1 |
| Cooper, ME; Cox, AJ; Gilbert, RE; Kelly, DJ; Tolcos, M; Wilkinson-Berka, JL | 1 |
| Lin, S; Wen, H | 1 |
| Dagistanli, FK; Erek, E; Kalender, B; Oztürk, M; Tunçdemir, M; Uysal, O; Yegenaga, I | 1 |
| Du, YC; Xu, JY; Zhang, SJ | 1 |
| Banfi, C; Brioschi, M; Crippa, V; de Gasparo, M; Gelosa, P; Gianazza, E; Gianella, A; Guerrini, U; Nobili, E; Sironi, L; Tremoli, E | 1 |
| Gong, ZJ; Huang, YQ; Ruan, P; Song, SL | 1 |
| Khalil, N; Mancini, GB | 1 |
| Liu, F; Xu, QY; Ye, YQ | 1 |
| Gong, HP; Li, L; Ma, X; Miao, Y; Sun, H; Zhang, W; Zhang, Y; Zhong, M | 1 |
| Akdag, I; Filiz, G; Gullulu, M; Kahvecioglu, S; Savci, V | 1 |
| Chen, N; Shi, H; Shi, W; Wang, W; Yu, H; Zhang, B | 1 |
| He, Y; Huang, Q; Jiang, J; Li, M; Liu, X; Ma, D; Wang, S; Xu, G; Yao, Y; Zhou, J; Zou, R | 1 |
| Akashiba, A; Ishimitsu, T; Matsuoka, H; Ono, H; Ono, Y | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Lai, ZF; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E | 1 |
| Lei, S; Lyu, C; Shao, Y; Wang, Q; Wu, C; Yuan, Q | 1 |
| Arimura, T; Goto, M; Imaizumi, S; Iwata, A; Kuwano, T; Matsuo, Y; Miura, S; Saku, K; Suematsu, Y; Yahiro, E | 1 |
| Cao, S; Huang, X; Jiang, X; Kang, Y; Mei, Q; Qin, D; Wu, AG; Wu, J; Yang, J; Ye, Y; Zhang, C | 1 |
| Abbas, SS; Gebril, SM; Hassan, FE; Hassanin, SO; Mahmoud, MO; Schaalan, MF | 1 |
21 other study(ies) available for valsartan and transforming growth factor beta
| Article | Year |
|---|---|
Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury.
Topics: Aldosterone; Angiotensin II; Animals; Animals, Genetically Modified; Blood Pressure; Body Weight; Cardiovascular Diseases; Fibroblast Growth Factor 2; Heart; Immunohistochemistry; Mineralocorticoid Receptor Antagonists; NF-kappa B; Organ Size; Platelet-Derived Growth Factor; Rats; Receptors, Mineralocorticoid; Renin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tetrazoles; Transcription Factor AP-1; Transforming Growth Factor beta; Valine; Valsartan | 2001 |
Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1).
Topics: Angiotensin Receptor Antagonists; Animals; Blotting, Northern; Bosentan; Collagen; Endothelin Receptor Antagonists; Female; Fibroblasts; Hemodynamics; Hypertrophy, Left Ventricular; Immunohistochemistry; Macrophages; Monocytes; Myocardial Infarction; Myocardium; Procollagen; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Tetrazoles; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan; Ventricular Dysfunction, Left | 2001 |
Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Collagen; Drug Combinations; Fibrosis; Fosinopril; Male; Myocardial Infarction; Myocardium; Random Allocation; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan; Ventricular Remodeling | 2001 |
Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive Agents; Apoptosis; Atrophy; Autoradiography; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epidermal Growth Factor; Female; Fibrosis; Gene Expression; In Situ Hybridization; In Situ Nick-End Labeling; Kidney Tubules; Nephritis, Interstitial; Perindopril; Rats; Renin-Angiotensin System; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2002 |
[Renal protective effect of valsartan in diabetic rats].
Topics: Animals; Collagen Type IV; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Down-Regulation; Fibronectins; Kidney; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan | 1999 |
Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enalapril; Female; Immunoenzyme Techniques; Immunohistochemistry; Kidney; Organ Size; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2002 |
Effects of angiotensin II receptor antagonist on expression of collagen III, collagen V, and transforming growth factor beta1 in the airway walls of sensitized rats.
Topics: Angiotensin Receptor Antagonists; Animals; Asthma; Bronchi; Collagen Type III; Collagen Type V; Immunization; Male; Ovalbumin; Random Allocation; Rats; Rats, Wistar; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2004 |
Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Blood Pressure; Body Weight; Brain; Chemokine CCL2; Immunohistochemistry; Interleukin-1; Kidney; Magnetic Resonance Imaging; Male; Proteinuria; Rats; Rats, Inbred SHR; RNA, Messenger; Stroke; Survival Analysis; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2004 |
[Effects of perindopril and valsartan on the expression of TGF beta 1 and TGF beta receptor II mRNA, Smad3 and Smad7 in experimental hepatic fibrotic rats].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Carbon Tetrachloride; Carbon Tetrachloride Poisoning; Female; Liver Cirrhosis, Experimental; Male; Perindopril; Random Allocation; Rats; Rats, Wistar; Receptors, Transforming Growth Factor beta; RNA, Messenger; Smad3 Protein; Smad7 Protein; Tetrazoles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan | 2004 |
Angiotensin II type 1 receptor blocker inhibits pulmonary injury.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antimetabolites, Antineoplastic; Bleomycin; Blotting, Western; Collagen; Connective Tissue Growth Factor; Enzyme-Linked Immunosorbent Assay; Female; Fibrosis; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Lung; Macrophages; Rats; Rats, Sprague-Dawley; Tetrazoles; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan | 2005 |
[Effects of valsartan on bleomycin-induced pulmonary fibrosis in rats and the expression of hepatocyte growth factor in lung tissue].
Topics: Animals; Hepatocyte Growth Factor; Lung; Male; Pulmonary Fibrosis; Rats; Rats, Wistar; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2005 |
[Mechanism of reversion of myocardial interstitial fibrosis in diabetic cardiomyopathy by valsartan].
Topics: Animals; Antihypertensive Agents; Blood Pressure; Blotting, Western; Cardiomyopathy, Hypertrophic; Diabetes Mellitus, Experimental; Fibrosis; Heart; Male; Myocardium; Random Allocation; Rats; Rats, Wistar; Receptors, Angiotensin; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tetrazoles; Thrombospondin 1; Transforming Growth Factor beta; Valine; Valsartan | 2006 |
Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cell Proliferation; Disease Models, Animal; Diuretics; Fibrosis; Glomerulonephritis, Membranoproliferative; Ki-67 Antigen; Kidney; Mineralocorticoid Receptor Antagonists; Rats; Rats, Sprague-Dawley; Spironolactone; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2006 |
Peritubular capillary loss is ameliorated by ramipril or valsartan treatment.
Topics: Animals; Antihypertensive Agents; Capillaries; Gene Expression Regulation; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Tubules; Male; Microcirculation; Ramipril; Rats; Rats, Sprague-Dawley; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2008 |
Telmisartan but not valsartan inhibits TGF-beta-mediated accumulation of extracellular matrix via activation of PPARgamma.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Cells, Cultured; Extracellular Matrix; Glomerulosclerosis, Focal Segmental; Mesangial Cells; PPAR gamma; Rats; Telmisartan; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2008 |
Valsartan improves L-NAME-exacerbated cardiac fibrosis with TGF-ß inhibition and apoptosis induction in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Caspase 3; Fibrosis; Hypertension; Male; Myocardium; NG-Nitroarginine Methyl Ester; Rats; Rats, Inbred SHR; RNA; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan; Ventricular Remodeling | 2008 |
Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice.
Topics: Albuminuria; Amides; Animals; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Synergism; Fumarates; Kidney Glomerulus; Losartan; Male; Mice; Mice, Inbred C57BL; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2010 |
[Valsartan inhibits angiotensin II-Notch signaling of mesangial cells induced by high glucose].
Topics: Angiotensin II; Animals; Blotting, Western; Cells, Cultured; Dipeptides; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fibronectins; Glucose; Mesangial Cells; Rats; Receptor, Notch1; Signal Transduction; Time Factors; Transforming Growth Factor beta; Valsartan | 2016 |
LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Diabetes Mellitus, Experimental; Drug Combinations; Fibrosis; Heart; Heart Failure; Heart Ventricles; Male; Mice; Mice, Inbred C57BL; Myocardial Reperfusion Injury; Myocardium; Neprilysin; RNA, Messenger; Stroke Volume; Tetrazoles; Transforming Growth Factor beta; Valsartan | 2016 |
Tandospirone enhances the anti-myocardial fibrosis effect of valsartan in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Cardiomyopathies; Drug Synergism; Fibrosis; Gene Expression; Hypertension; Immunohistochemistry; Isoindoles; Male; Models, Biological; Myocardium; Piperazines; Pyrimidines; Rats; Rats, Inbred SHR; Serotonin Receptor Agonists; Smad3 Protein; Transforming Growth Factor beta; Valsartan | 2020 |
LCZ696 (sacubitril/valsartan) protects against cyclophosphamide-induced nephrotoxicity in adult male rats: Up-regulation of Apelin-13/ACE2, miR-200, and down-regulation of TGF-β/SMAD 2/3 and miR-192.
Topics: Aminobutyrates; Angiotensin-Converting Enzyme 2; Animals; Biphenyl Compounds; Cyclophosphamide; Down-Regulation; Drug Combinations; Intercellular Signaling Peptides and Proteins; Kidney; Male; MicroRNAs; Rats; Rats, Wistar; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta; Up-Regulation; Valsartan | 2022 |